Single centre open label pilot clinical trial to assess the efficacy of a combination of 1g Psorakot oral tablets (two tablets thrice daily) and Psorakot gel external application (twice daily) in subjects with moderate to severe psoriasis over a period of 6 weeks

Clinfound Clinical Research Services Pvt Ltd0 个研究点目标入组 25 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with active, stable psoriasis defined by the following criteria:
•a.DLQI > 10 at baseline
•2.Patients who are willing to sign the informed consent form and agree to return to follow-up visits.

•1.Patients who were making use of biologics, corticosteroids or nonsteroidal anti-inflammatory and non-steroid, or who made use of these topical medications until 15 days before inclusion or 30 days before inclusion when the administration was orally.
•2.Patients with evidence of Skin conditions other than psoriasis.
•3.Patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria and they were making use of antibiotic or antifungal.
•4.Patients using Psoralen plus ultraviolet radiation (PUVA), cyclosporine, alefacept, methotrexate, acitretin, or any other systemic anti-psoriasis therapy within 28 days of study drug initiation
•5.Pregnant and/or nursing women
•6.Patients using oral anticoagulants

发起方

Clinfound Clinical Research Services Pvt Ltd